Application/Technical Notes



Applying transdermal patches to deliver active pharmaceutical ingredients (API) through the human skin provides numerous advantages compared to traditional dosage forms. Therefore, more and more efforts are devoted to the development of these formulations. To help the evolution of the patches, Skin PAMPA provides a unique opportunity to continuously estimate the performance of the patch during the early stages of development. This can help the formulator test various combinations, aiming to reach the most promising matrix for each API.


Studying the permeation properties of formulations is crucial in all stages of dermal and transdermal formulation development. Most of the available methods suffer from being labor-intensive and having poor reproducibility. Skin PAMPA technology is a useful tool for the early stages of development as it is an easy-to-use, cost-effective, and standardized model with significantly lower variation compared to most of the available methods. This technical note provides an example of studying three commercially available diclofenac formulations using Skin PAMPA model.